Ricardo Signs Deal to Support Singer With Bespoke Manual Transmissions
Ricardo has signed a multi-year deal to supply transmissions for Porsche 911s reimagined by Singer
Ricardo, a global strategic, environmental, and engineering consulting company, has signed a deal to supply bespoke, manual transmissions to Singer’s operations in the US and UK.
The transmissions will be exclusive to Singer and will initially be available to owners who request Singer’s Classic Turbo or DLS Turbo restoration services for their Type 964 Porsche 911.
Singer arrived on the automotive scene with their Classic services in 2009. Since then, the company has developed restoration services allowing owners to personalise both naturally aspirated and turbocharged cars. A Porsche 911 Reimagined by Singer is a rare machine, bringing together iconic design with twenty-first century engineering and material science.
Ricardo’s design team will ensure that the transmissions meets the exacting, high performance needs of Singer’s clients. The focus is on delivering an H-pattern transmission able to accommodate the additional demands that a turbocharged car places on the drivetrain. Designed to seamlessly integrate into the existing chassis, the transmission will enable smooth, engaging gear shift operations despite the increased torque and power demands.
The transmissions will be manufactured and tested at Ricardo’s state of the art Midlands Technical Centre in Leamington Spa, UK.
Richard Guest, Managing Director of Performance Products at Ricardo, said: “We are delighted to be working on this significant multi-year project, supplying Singer in the UK and US with a series of transmissions that will support the growth of their customer base. The passion and detail that they demonstrate through these vehicles is a great match with the drivetrain expertise that Ricardo can provide. We look forward to supporting the Singer team on this project and building on our existing relationship.”
Mazen Fawaz, Chief Strategy Officer, Singer Group, notes: “Our approach is always based around execution without compromise. This leads us to seek out and collaborate with the best in the world. An exceptional, truly engaging, manual transmission is an essential part of the remarkable sports cars that we pursue, on behalf of some of the most discerning drivers in the world. We look forward to continuing this pursuit in collaboration with Ricardo.”
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering innovative cross-sector sustainable outcomes to support energy transition, environmental services together with safe and smart transport. Our global team of consultants, environmental specialists, engineers and scientists support our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
About Singer
Founded in California in 2009, Singer represents a philosophy simply expressed as A Relentless Pursuit of Excellence.
The company has become renowned for its collaboration with owners of the air-cooled Porsche 911 to reimagine bespoke restorations. Singer’s philosophy embodies:
- A highly personalized approach and exquisite execution
- A passionate focus on iconic design and a homage to the world’s most iconic sportscars.
- Modern engineering and material science combined with jewel-like details.
- A deep connection with California and its automotive zeitgeist.
Visit www.singervehicledesign.com
Singer is not sponsored, associated, approved, endorsed nor, in any way, affiliated with Porsche Cars North America, Inc., or Dr. Ing. h.c. F. Porsche, AG. Dr. Ing. h.c. F. Porsche AG is the owner of numerous trademarks, both registered and unregistered, including, without limitation, the Porsche Crest®, Porsche®, and the model numbers and names and the distinctive shapes of the Porsche automobiles, such as the federally registered 911 automobile. Any mention of Porsche Cars North America, Inc., or Dr. Ing. h.c. F. Porsche, AG. trademarked names or other marks is for purpose of reference only.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212195492/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom